LiquidiaLQDA +6.08%67 PEG Ratio is 80.20 as of Jun. 30, 2026. GuruFocus rates LQDA with a GF Score™ of 67/100 and a GF Value™ of $218.97 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 346 Drug Manufacturers companies, Liquidia ranks worse than 98.84% on this metric.
PE Ratio without NRI / 5-Year EBITDA Growth Rate*
PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, Liquidia's PE Ratio without NRI is 569.43. Liquidia's 5-Year EBITDA growth rate is 7.10%. Therefore, Liquidia's PEG Ratio for today is 80.20.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Liquidia's PEG Ratio or its related term are showing as below:
LQDA'
s PEG Ratio Range Over the Past 10 Years
Min: 0 Med: 0 Max: 81.12
Current: 80.21
During the past 10 years, Liquidia's highest PEG Ratio was 81.12. The lowest was 0.00. And the median was 0.00.
LQDA's PEG Ratio is ranked worse than 98.84% of 346
companies
in the Drug Manufacturers industry
Industry Median: 1.695
vs LQDA: 80.21
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
Liquidia (NAS:LQDA) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Liquidia PEG Ratio Related Terms
Liquidia PEG Ratio Historical Data
* Premium members only.
The historical data trend for Liquidia's PEG Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Liquidia's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Liquidia PEG Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Liquidia's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Liquidia's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Liquidia (LQDA) has a PEG Ratio of 80.20 as of Jun. 30, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Liquidia and its competitors. According to the industry distribution chart, Liquidia ranks #342 out of 346 companies in the Drug Manufacturers industry, placing it in the top 98.8%.
Is Liquidia's PEG Ratio too high?
Liquidia's current PEG Ratio is 80.20. The Drug Manufacturers industry median PEG Ratio is 1.70. Liquidia's value of 80.20 is 4631.6% above this industry median. Based on the distribution chart, Liquidia ranks #342 out of 346 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Liquidia has a GF Score™ of 67/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Liquidia's PEG Ratio compare to LNTH and HIMS?
According to the Drug Manufacturers industry distribution chart, Liquidia ranks #342 out of 346 companies for PEG Ratio. This places Liquidia in the lower half of its industry. The industry median PEG Ratio is 1.70. Liquidia's value of 80.20 is 4631.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Drug Manufacturers company?
The median PEG Ratio among Drug Manufacturers companies is 1.70, based on 346 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Liquidia's current PEG Ratio of 80.20 is 4631.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Liquidia and its competitors. For the Drug Manufacturers industry, the median PEG Ratio is 1.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Liquidia's current PEG Ratio is 80.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Liquidia stock overvalued right now?
Based on GuruFocus' analysis, Liquidia (LQDA) is currently considered Possible Value Trap. The stock's GF Value™ is $218.97, compared to a current price of $79.72 — trading 63.6% below its estimated fair value. The current PEG Ratio is 80.20 and 4631.6% above the Drug Manufacturers industry median of 1.70. Liquidia's overall GF Score™ is 67/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For Liquidia (LQDA), the current PEG Ratio is 80.20 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Liquidia (LQDA) Overvalued in 2026?
Based on GuruFocus' analysis, Liquidia stock appears to be undervalued.
The current stock price of $79.72 is trading 63.6% below its estimated GF Value™ of $218.97.
GuruFocus considers Liquidia to be Possible Value Trap.
Key valuation signals for LQDA:
PEG Ratio: 80.20
GF Value™: $218.97 vs. price of $79.72 (63.6% below fair value)
Industry Position: 4631.6% above the Drug Manufacturers median (#342 of 346)
No single metric tells the full story. See the LQDA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.
67GF Score
Get the complete analysis for LQDA
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LQDA has been successfully added to your 
